NCT Number,Study Title,Study URL,Study Status,Conditions,Interventions,Sponsor,Collaborators,Study Type,Completion Date
NCT05552859,Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment,https://clinicaltrials.gov/study/NCT05552859,TERMINATED,Type 2 Diabetes Mellitus|Renal Impairment,DRUG: Insulin glargine 300 U/mL|DRUG: Insulin degludec 100 U/mL,Sanofi,,INTERVENTIONAL,2023-08-04
NCT05413369,iGlarLixi vs IDegAsp in Chinese Participants After OAD(s),https://clinicaltrials.gov/study/NCT05413369,COMPLETED,Type 2 Diabetes Mellitus,DRUG: Insulin glargine/Lixisenatide|DRUG: IDegAsp|DRUG: Metformin|DRUG: SGLT2 inhibitor,Sanofi,,INTERVENTIONAL,2023-10-20
NCT05179603,A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205],https://clinicaltrials.gov/study/NCT05179603,TERMINATED,Classic Hodgkin Lymphoma|Diffuse Large B-cell Lymphoma,DRUG: THOR-707|DRUG: Pembrolizumab,Sanofi,Merck Sharp & Dohme LLC,INTERVENTIONAL,2024-09-06
NCT05137041,Efficacy and Safety of FIRTECH in Patients With Mild to Moderate Acute Low Back Pain,https://clinicaltrials.gov/study/NCT05137041,COMPLETED,Low Back Pain,DEVICE: ITP FIRTECH,Sanofi,,INTERVENTIONAL,2022-11-22
NCT05132569,Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis,https://clinicaltrials.gov/study/NCT05132569,TERMINATED,Myasthenia Gravis,DRUG: Tolebrutininb|DRUG: Placebo,Sanofi,,INTERVENTIONAL,2023-02-21
NCT05132127,Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan,https://clinicaltrials.gov/study/NCT05132127,COMPLETED,Cold Agglutinin Disease,DRUG: sutimlimab,Sanofi,,INTERVENTIONAL,2022-11-15
NCT05128773,"Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity",https://clinicaltrials.gov/study/NCT05128773,TERMINATED,Breast Cancer,DRUG: Amcenestrant|DRUG: Tamoxifen|DRUG: Amcenestrant-matching placebo|DRUG: Tamoxifen-matching placebo,Sanofi,"Breast International Group|Alliance Foundation Trials, LLC.|European Organisation for Research and Treatment of Cancer - EORTC",INTERVENTIONAL,2022-10-13
NCT05114590,Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus,https://clinicaltrials.gov/study/NCT05114590,COMPLETED,Type 2 Diabetes Mellitus,DRUG: Insulin glargine/Lixisenatide,Sanofi,,INTERVENTIONAL,2023-04-14
NCT05104567,A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203),https://clinicaltrials.gov/study/NCT05104567,COMPLETED,Oesophageal Squamous Cell Carcinoma|Gastric Cancer|Hepatocellular Carcinoma|Colorectal Cancer|Oesophageal Adenocarcinoma,DRUG: THOR-707|DRUG: Pembrolizumab|DRUG: Cetuximab,Sanofi,Merck Sharp & Dohme LLC,INTERVENTIONAL,2024-09-09
NCT05071053,Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer,https://clinicaltrials.gov/study/NCT05071053,TERMINATED,Adenocarcinoma Gastric|Gastrooesophageal Cancer,DRUG: Ramucirumab (CYRAMZA®)|DRUG: Tusamitamab ravtansine (SAR408701),Sanofi,,INTERVENTIONAL,2024-11-05
NCT05061420,A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204),https://clinicaltrials.gov/study/NCT05061420,TERMINATED,Squamous Cell Carcinoma of Head and Neck,DRUG: Pembrolizumab|DRUG: SAR444245 (Thor-707)|DRUG: Cetuximab,Sanofi,Merck Sharp & Dohme LLC,INTERVENTIONAL,2024-11-26
NCT05049122,Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52),https://clinicaltrials.gov/study/NCT05049122,COMPLETED,Chronic Rhinosinusitis With Nasal Polyps,DRUG: Dupilumab SAR231893,Sanofi,Regeneron Pharmaceuticals,INTERVENTIONAL,2023-07-05
NCT04914897,A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202),https://clinicaltrials.gov/study/NCT04914897,TERMINATED,Pleural Mesothelioma|Non-small Cell Lung Cancer,DRUG: THOR-707|DRUG: Pembrolizumab,Sanofi,Merck Sharp & Dohme LLC,INTERVENTIONAL,2024-10-17
NCT04913220,A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201),https://clinicaltrials.gov/study/NCT04913220,TERMINATED,Malignant Melanoma|Squamous Cell Carcinoma of Skin,DRUG: THOR-707|DRUG: Cemiplimab,Sanofi,,INTERVENTIONAL,2025-02-18
NCT04879628,Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis,https://clinicaltrials.gov/study/NCT04879628,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,DRUG: SAR441344 IV|DRUG: placebo IV|DRUG: SAR441344 SC|DRUG: placebo SC|DRUG: MRI contrast-enhancing preparations,Sanofi,,INTERVENTIONAL,2027-08-23
NCT04823130,Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis,https://clinicaltrials.gov/study/NCT04823130,COMPLETED,Dermatitis Atopic,DRUG: Dupilumab (SAR231893),Sanofi,Regeneron Pharmaceuticals,INTERVENTIONAL,2022-08-30
NCT04781816,Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus,https://clinicaltrials.gov/study/NCT04781816,COMPLETED,Cutaneous Lupus Erythematosus,DRUG: SAR443122|DRUG: Placebo,Sanofi,,INTERVENTIONAL,2023-06-26
NCT04718870,Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis,https://clinicaltrials.gov/study/NCT04718870,COMPLETED,Dermatitis Atopic,DRUG: Dupilumab SAR231893,Sanofi,Regeneron Pharmaceuticals,INTERVENTIONAL,2022-11-30
NCT04705051,Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat,https://clinicaltrials.gov/study/NCT04705051,TERMINATED,Congenital Cystic Kidney Disease,DRUG: Venglustat GZ402671,Sanofi,,INTERVENTIONAL,2021-07-13
NCT04681729,Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS),https://clinicaltrials.gov/study/NCT04681729,COMPLETED,Cold Urticaria,DRUG: Dupilumab SAR231893|DRUG: Placebo|DRUG: Non sedating H1-antihistamine,Sanofi,Regeneron Pharmaceuticals,INTERVENTIONAL,2023-04-20
NCT04678856,Dupilumab in CRSsNP,https://clinicaltrials.gov/study/NCT04678856,COMPLETED,Chronic Rhinosinusitis Without Nasal Polyps|Sinusitis|Chronic Sinusitis|Sinus Disorder|Respiratory Disorder,DRUG: Dupilumab SAR231893|DRUG: Placebo,Sanofi,Regeneron Pharmaceuticals,INTERVENTIONAL,2024-01-29
NCT04661033,"Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)",https://clinicaltrials.gov/study/NCT04661033,TERMINATED,Warm Autoimmune Hemolytic Anemia (wAIHA),DRUG: Isatuximab SAR650984,Sanofi,,INTERVENTIONAL,2023-06-26
NCT04583618,Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.,https://clinicaltrials.gov/study/NCT04583618,COMPLETED,Pneumococcal Immunization,BIOLOGICAL: Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb|BIOLOGICAL: Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI|BIOLOGICAL: Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII|BIOLOGICAL: Pneumococcal 13 - valent conjugate vaccine-Prevnar 13|BIOLOGICAL: Pneumococcal Vaccine Polyvalent-Pneumovax 23,Sanofi,,INTERVENTIONAL,2022-01-20
NCT04572841,"Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)",https://clinicaltrials.gov/study/NCT04572841,COMPLETED,Sjögren's Syndrome|Sjogren's Syndrome,DRUG: SAR441344|DRUG: Placebo,Sanofi,,INTERVENTIONAL,2024-02-09
NCT04502862,"A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma",https://clinicaltrials.gov/study/NCT04502862,COMPLETED,Asthma,DRUG: SAR231893|DRUG: Placebo,Sanofi,Regeneron Pharmaceuticals,INTERVENTIONAL,2023-11-10
NCT04478266,Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer,https://clinicaltrials.gov/study/NCT04478266,TERMINATED,Breast Cancer,DRUG: Amcenestrant-matching placebo|DRUG: SAR439859|DRUG: Palbociclib|DRUG: Letrozole|DRUG: Goserelin|DRUG: Letrozole-matching placebo,Sanofi,,INTERVENTIONAL,2023-05-26
NCT04447417,Dupilumab Skin Barrier Function Study in Atopic Dermatitis,https://clinicaltrials.gov/study/NCT04447417,COMPLETED,Atopic Dermatitis,DRUG: Dupilumab SAR231893,Sanofi,Regeneron Pharmaceuticals,INTERVENTIONAL,2021-06-17
NCT04400318,The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma,https://clinicaltrials.gov/study/NCT04400318,COMPLETED,Asthma,DRUG: Dupilumab|DRUG: Placebo,Sanofi,Regeneron Pharmaceuticals,INTERVENTIONAL,2023-08-21
NCT04394624,Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04),https://clinicaltrials.gov/study/NCT04394624,TERMINATED,Non-small Cell Lung Cancer Metastatic,DRUG: SAR408701|DRUG: ramucirumab|DRUG: pembrolizumab,Sanofi,,INTERVENTIONAL,2024-10-24
NCT04368429,"Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age",https://clinicaltrials.gov/study/NCT04368429,COMPLETED,Meningococcal Immunisation (Healthy Volunteers),"BIOLOGICAL: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine)|BIOLOGICAL: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine",Sanofi,,INTERVENTIONAL,2020-11-07
NCT04327388,Sarilumab COVID-19,https://clinicaltrials.gov/study/NCT04327388,COMPLETED,Corona Virus Infection,DRUG: Sarilumab SAR153191|DRUG: Placebo,Sanofi,Regeneron Pharmaceuticals,INTERVENTIONAL,2020-09-02
NCT04294459,"Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation",https://clinicaltrials.gov/study/NCT04294459,TERMINATED,Immune System Disorder,DRUG: Isatuximab SAR650984|DRUG: Acetaminophen (paracetamol) or equivalent|DRUG: Ranitidine or equivalent|DRUG: Diphenhydramine or equivalent|DRUG: Methylprednisolone or equivalent|DRUG: Montelukast or equivalent,Sanofi,,INTERVENTIONAL,2022-05-02
NCT04202679,"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)",https://clinicaltrials.gov/study/NCT04202679,COMPLETED,Neurodermatitis,DRUG: Dupilumab SAR231893|DRUG: Placebo|DRUG: Moisturizers|DRUG: Low to medium potent topical corticosteroids|DRUG: Topical calcineurin inhibitors,Sanofi,Regeneron Pharmaceuticals,INTERVENTIONAL,2021-11-22
NCT04191382,"Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer",https://clinicaltrials.gov/study/NCT04191382,TERMINATED,Breast Cancer,DRUG: Amcenestrant (SAR439859)|DRUG: Letrozole,Sanofi,,INTERVENTIONAL,2021-05-28
NCT04183335,"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)",https://clinicaltrials.gov/study/NCT04183335,COMPLETED,Neurodermatitis,DRUG: Dupilumab SAR231893|DRUG: Placebo|DRUG: Moisturizers|DRUG: Low to medium potent topical corticosteroids|DRUG: Topical calcineurin inhibitors,Sanofi,Regeneron Pharmaceuticals,INTERVENTIONAL,2022-02-03
NCT04154956,"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients",https://clinicaltrials.gov/study/NCT04154956,ACTIVE_NOT_RECRUITING,Non-small Cell Lung Cancer Metastatic,DRUG: SAR408701|DRUG: Docetaxel,Sanofi,,INTERVENTIONAL,2026-03-31
NCT04075513,Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients,https://clinicaltrials.gov/study/NCT04075513,COMPLETED,Type 1 Diabetes Mellitus,"DRUG: Insulin glargine, 300 U/ml|DRUG: Insulin degludec, 100U/ml|DRUG: Background therapy: Rapid acting insulin analogs",Sanofi,,INTERVENTIONAL,2021-09-16
NCT04059484,Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer,https://clinicaltrials.gov/study/NCT04059484,TERMINATED,Breast Cancer Metastatic,DRUG: Amcenestrant|DRUG: Fulvestrant|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane|DRUG: Tamoxifen,Sanofi,,INTERVENTIONAL,2025-01-02
NCT04033367,"SAR231893-LPS15497- ""Dupilumab Effect on Sleep in AD Patients""",https://clinicaltrials.gov/study/NCT04033367,COMPLETED,Atopic Dermatitis,DRUG: Dupilumab|DRUG: Placebo,Sanofi,Regeneron Pharmaceuticals,INTERVENTIONAL,2021-10-06
NCT03930732,"Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation",https://clinicaltrials.gov/study/NCT03930732,COMPLETED,Chronic Obstructive Pulmonary Disease,DRUG: Dupilumab SAR231893|DRUG: Inhaled Corticosteroid|DRUG: Inhaled Long-Acting Beta Agonist|DRUG: Inhaled Long-Acting Muscarinic Antagonist|DRUG: Placebo,Sanofi,Regeneron Pharmaceuticals,INTERVENTIONAL,2023-05-02
NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,https://clinicaltrials.gov/study/NCT03889639,COMPLETED,Relapsing Multiple Sclerosis,DRUG: SAR442168|DRUG: Placebo|DRUG: Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI),Sanofi,,INTERVENTIONAL,2020-01-02
NCT03874715,Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,https://clinicaltrials.gov/study/NCT03874715,COMPLETED,Type 1 Diabetes Mellitus,DRUG: Insulin Aspart SAR341402|DRUG: Insulin Aspart|DRUG: Insulin glargine U100,Sanofi,,INTERVENTIONAL,2020-07-08
NCT03860844,Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia,https://clinicaltrials.gov/study/NCT03860844,TERMINATED,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia,DRUG: Isatuximab|DRUG: Dexamethasone or equivalent|DRUG: Fludarabine|DRUG: Cytarabine|DRUG: Liposomal daunorubicin|DRUG: Daunorubicin (nonliposomal)|DRUG: Idarubicin|DRUG: Filgrastim or equivalent|DRUG: Mitoxantrone|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Pegaspargase (PEG) Asparaginase|DRUG: Cyclophosphamide|DRUG: Etoposide|DRUG: Methotrexate|DRUG: L - Asparginase|DRUG: Hydroxyurea|DRUG: L - Asparaginase (Erwinase),Sanofi,,INTERVENTIONAL,2023-05-26
NCT03770728,Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea,https://clinicaltrials.gov/study/NCT03770728,TERMINATED,Type 2 Diabetes Mellitus,DRUG: Efpeglenatide SAR439977|DRUG: Placebo|DRUG: Background therapy: Metformin alone or in combination with SU,Sanofi,Hanmi Pharmaceutical Company Limited,INTERVENTIONAL,2020-12-27
NCT05608005,Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older,https://clinicaltrials.gov/study/NCT05608005,COMPLETED,Influenza|Healthy Volunteers,BIOLOGICAL: Panblok + MF59 Dose 1|BIOLOGICAL: Panblok + MF59 Dose 2|BIOLOGICAL: Unadjuvanted Panblok Dose 3,"Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2024-02-13
NCT05513391,Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years,https://clinicaltrials.gov/study/NCT05513391,TERMINATED,Influenza Immunization,BIOLOGICAL: Recombinant influenza vaccine (RIV4)|BIOLOGICAL: Quadrivalent influenza vaccine (IIV4),"Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2023-10-03
NCT05513053,Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.,https://clinicaltrials.gov/study/NCT05513053,COMPLETED,Influenza Immunization,BIOLOGICAL: Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH,"Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2023-10-27
NCT05144945,Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea,https://clinicaltrials.gov/study/NCT05144945,COMPLETED,Influenza (Healthy Volunteers),BIOLOGICAL: Quadrivalent Recombinant Influenza Vaccine (RIV4)|BIOLOGICAL: Quadrivalent inactivated influenza vaccine (IIV4),"Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2022-09-01
NCT05050318,"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively",https://clinicaltrials.gov/study/NCT05050318,COMPLETED,Influenza Immunization|Healthy Volunteers,"BIOLOGICAL: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation|BIOLOGICAL: Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation","Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2021-11-10
NCT05011123,Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia,https://clinicaltrials.gov/study/NCT05011123,ACTIVE_NOT_RECRUITING,Yellow Fever,BIOLOGICAL: Yellow fever vaccine (produced on serum-free Vero cells)|BIOLOGICAL: Yellow fever vaccine,"Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2027-04-23
NCT04969276,Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine,https://clinicaltrials.gov/study/NCT04969276,COMPLETED,Influenza Immunization|Healthy Volunteers,BIOLOGICAL: Quadrivalent Inactivated Influenza High Dose|BIOLOGICAL: COVID-19 mRNA Vaccine (nucleoside modified),"Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2022-02-08
NCT04942210,Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA,https://clinicaltrials.gov/study/NCT04942210,ACTIVE_NOT_RECRUITING,Yellow Fever|Healthy Volunteers,BIOLOGICAL: Yellow fever vaccine (produced on serum-free Vero cells)|BIOLOGICAL: Yellow fever vaccine,"Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2027-06-29
NCT04936685,Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers,https://clinicaltrials.gov/study/NCT04936685,ACTIVE_NOT_RECRUITING,Meningococcal Immunisation|Healthy Volunteers,"BIOLOGICAL: Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine","Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2027-12-26
NCT04798027,Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older,https://clinicaltrials.gov/study/NCT04798027,TERMINATED,COVID-19,BIOLOGICAL: SARS-CoV-2 mRNA vaccine formulation 1|BIOLOGICAL: SARS-CoV-2 mRNA vaccine formulation 2|BIOLOGICAL: SARS-CoV-2 mRNA vaccine formulation 3|BIOLOGICAL: Placebo (0.9% normal saline),"Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2022-06-27
NCT04762680,Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older,https://clinicaltrials.gov/study/NCT04762680,COMPLETED,COVID-19,"BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1|BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2|BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4|BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03","Sanofi Pasteur, a Sanofi Company",GlaxoSmithKline,INTERVENTIONAL,2023-06-29
NCT04551677,"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively",https://clinicaltrials.gov/study/NCT04551677,COMPLETED,Influenza Immunization|Healthy Volunteers,"BIOLOGICAL: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation|BIOLOGICAL: Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation","Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2020-12-18
NCT04544267,Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age,https://clinicaltrials.gov/study/NCT04544267,TERMINATED,Influenza,"BIOLOGICAL: Quadrivalent influenza vaccine, high-dose|BIOLOGICAL: Quadrivalent influenza vaccine, standard dose","Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2021-06-02
NCT04537234,Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older,https://clinicaltrials.gov/study/NCT04537234,COMPLETED,Influenza (Healthy Volunteers),BIOLOGICAL: High-Dose Quadrivalent Influenza Vaccine|BIOLOGICAL: Standard-Dose Quadrivalent Influenza Vaccine,"Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2021-02-09
NCT04537208,Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older,https://clinicaltrials.gov/study/NCT04537208,COMPLETED,COVID-19 (Healthy Volunteers),BIOLOGICAL: CoV2 preS dTM-AF03 (low-dose)|BIOLOGICAL: CoV2 preS dTM-AF03 (high-dose)|BIOLOGICAL: CoV2 preS dTM-AS03 (low-dose)|BIOLOGICAL: CoV2 preS dTM-AS03 (high-dose)|BIOLOGICAL: CoV2 preS dTM (high-dose) without adjuvant|BIOLOGICAL: Placebo (0.9% normal saline),"Sanofi Pasteur, a Sanofi Company",GlaxoSmithKline,INTERVENTIONAL,2021-11-19
NCT04498832,Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older,https://clinicaltrials.gov/study/NCT04498832,COMPLETED,Influenza Immunization|Healthy Volunteers,"BIOLOGICAL: High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)|BIOLOGICAL: Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)","Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2021-01-14
NCT04491877,Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers,https://clinicaltrials.gov/study/NCT04491877,COMPLETED,Respiratory Syncytial Virus Infection,BIOLOGICAL: RSV vaccine formulation 1|BIOLOGICAL: RSV vaccine formulation 2|BIOLOGICAL: Placebo,"Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2023-04-13
NCT04490018,"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents",https://clinicaltrials.gov/study/NCT04490018,COMPLETED,Meningococcal Immunisation|Healthy Volunteers,"BIOLOGICAL: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine)|BIOLOGICAL: Meningococcal group A, C, W-135, and Y conjugate vaccine|BIOLOGICAL: Human Papillomavirus 9-valent Vaccine (9vHPV)|BIOLOGICAL: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine (Tdap-IPV)","Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2022-05-11
NCT04398706,Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants,https://clinicaltrials.gov/study/NCT04398706,COMPLETED,Pneumococcal Immunisation|Diphtheria Immunisation|Tetanus Immunisation|Pertussis Immunisation|Hepatitis B Immunisation|Haemophilus Influenzae Type b Immunisation|Polio Immunisation|Measles Immunisation|Rubella Immunisation|Varicella Immunisation|Mumps Immunisation,"BIOLOGICAL: Pneumococcal Conjugate Vaccine formulation 1|BIOLOGICAL: Pneumococcal Conjugate Vaccine formulation 2|BIOLOGICAL: Pneumococcal Conjugate Vaccine formulation 3|BIOLOGICAL: Varicella Virus Vaccine Live|BIOLOGICAL: Measles, Mumps, and Rubella Virus Vaccine Live|BIOLOGICAL: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]|BIOLOGICAL: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)|BIOLOGICAL: Rotavirus Vaccine, Live, Oral, Pentavalent|BIOLOGICAL: Hepatitis B Vaccine* [Recombinant] *as applicable","Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2023-08-10
NCT04143061,"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa",https://clinicaltrials.gov/study/NCT04143061,COMPLETED,Meningococcal Immunization|Healthy Volunteers,"BIOLOGICAL: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine|BIOLOGICAL: Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine|BIOLOGICAL: Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine","Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2023-01-28
NCT04142242,Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49,https://clinicaltrials.gov/study/NCT04142242,COMPLETED,Meningococcal Infection (Healthy Volunteers),"BIOLOGICAL: Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|OTHER: Blood sample","Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2022-05-25
NCT04137887,Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older,https://clinicaltrials.gov/study/NCT04137887,TERMINATED,Influenza (Healthy Volunteers),"BIOLOGICAL: Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD)|BIOLOGICAL: Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)","Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2020-05-31
NCT04127786,"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults",https://clinicaltrials.gov/study/NCT04127786,COMPLETED,Rabies|Healthy Volunteers,BIOLOGICAL: Purified vero rabies vaccine - serum free - VRVg-2|BIOLOGICAL: Purified inactivated rabies vaccine - Verorab®|BIOLOGICAL: Purified inactivated rabies vaccine - Imovax® Rabies,"Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2025-04-24
NCT04109222,"Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively",https://clinicaltrials.gov/study/NCT04109222,COMPLETED,Influenza,"BIOLOGICAL: Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation|BIOLOGICAL: Fluzone High-Dose vaccine, 2019-2020 formulation","Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2019-12-10
NCT04084769,"Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)",https://clinicaltrials.gov/study/NCT04084769,COMPLETED,Meningococcal Immunisation (Healthy Volunteers),"BIOLOGICAL: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine|BIOLOGICAL: Meningococcal Group B vaccine (Trumenba®)|BIOLOGICAL: Meningococcal group B vaccine (Bexsero®)","Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2020-09-14
NCT04024228,Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older,https://clinicaltrials.gov/study/NCT04024228,COMPLETED,Influenza Immunization|Healthy Volunteers,"BIOLOGICAL: Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD)|BIOLOGICAL: High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation","Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2020-06-05
NCT03965962,Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults,https://clinicaltrials.gov/study/NCT03965962,COMPLETED,Rabies (Healthy Volunteers),BIOLOGICAL: VRVg-2|BIOLOGICAL: Purified Inactivated Rabies Vaccine|BIOLOGICAL: Human Diploid Cell Vaccine (HDCV)|BIOLOGICAL: Rabies immune globulin (human),"Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2021-07-01
NCT03890367,Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers,https://clinicaltrials.gov/study/NCT03890367,COMPLETED,Meningococcal Immunisation (Healthy Volunteers),"BIOLOGICAL: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine|BIOLOGICAL: Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine|BIOLOGICAL: Meningococcal group C polysaccharide Conjugate vaccine adsorbed","Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2020-10-14
NCT03869866,Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon,https://clinicaltrials.gov/study/NCT03869866,COMPLETED,Healthy Volunteers (Meningococcal Infection),"BIOLOGICAL: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine","Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2022-03-18
NCT02741128,Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults,https://clinicaltrials.gov/study/NCT02741128,COMPLETED,Dengue Fever|Dengue Hemorrhagic Fever|Human Immunodeficiency Virus,BIOLOGICAL: CYD Dengue Vaccine|BIOLOGICAL: Placebo (NaCl 0.9%) vaccine group,"Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,2023-01-19
NCT04759131,"Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A",https://clinicaltrials.gov/study/NCT04759131,COMPLETED,Hemophilia A,DRUG: efanesoctocog alfa (BIVV001),"Bioverativ, a Sanofi company",,INTERVENTIONAL,2023-01-18
NCT04680975,Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis,https://clinicaltrials.gov/study/NCT04680975,TERMINATED,Diffuse Cutaneous Systemic Sclerosis,DRUG: Belumosudil,"Kadmon, a Sanofi Company",,INTERVENTIONAL,2022-12-19
NCT04669600,A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP),https://clinicaltrials.gov/study/NCT04669600,COMPLETED,Immune Thrombocytopenia (ITP),DRUG: SAR445088 (BIVV020),"Bioverativ, a Sanofi company",,INTERVENTIONAL,2023-02-07
NCT04161495,"A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A",https://clinicaltrials.gov/study/NCT04161495,COMPLETED,Factor VIII Deficiency,BIOLOGICAL: efanesoctocog alfa (BIVV001),"Bioverativ, a Sanofi company",,INTERVENTIONAL,2022-02-03
NCT03919799,KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis,https://clinicaltrials.gov/study/NCT03919799,TERMINATED,System; Sclerosis|Diffuse Cutaneous Systemic Sclerosis,DRUG: Belumosudil (KD025)|DRUG: Placebo,"Kadmon, a Sanofi Company",,INTERVENTIONAL,2023-02-17
NCT03784898,Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada,https://clinicaltrials.gov/study/NCT03784898,COMPLETED,Multiple Sclerosis,OTHER: Blood draw for future biomarker analysis,"Genzyme, a Sanofi Company",,INTERVENTIONAL,2019-12-11
NCT02855268,Study of Lademirsen (SAR339375) in Patients With Alport Syndrome,https://clinicaltrials.gov/study/NCT02855268,TERMINATED,Alport Syndrome,DRUG: lademirsen (SAR339375)|DRUG: Placebo,"Genzyme, a Sanofi Company",,INTERVENTIONAL,2022-09-22
NCT04992546,"Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis",https://clinicaltrials.gov/study/NCT04992546,COMPLETED,Atopic Dermatitis,DRUG: PRN473 (SAR444727)|DRUG: Placebo,"Principia Biopharma, a Sanofi Company",,INTERVENTIONAL,2022-12-28
NCT03762265,A Study of PRN1008 in Patients With Pemphigus,https://clinicaltrials.gov/study/NCT03762265,TERMINATED,Pemphigus,DRUG: Rilzabrutinib|DRUG: Placebo,"Principia Biopharma, a Sanofi Company",,INTERVENTIONAL,2021-12-17
NCT05692154,A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis,https://clinicaltrials.gov/study/NCT05692154,COMPLETED,Seasonal Allergic Rhinitis,DRUG: Fexofenadine|DRUG: Placebo,"Opella Healthcare Group SAS, a Sanofi Company",,INTERVENTIONAL,2023-03-14
